FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891360972> ?p ?o ?g. }

• W2891360972 endingPage "34" @default.
• W2891360972 startingPage "29" @default.
• W2891360972 abstract "Despite therapeutic advancements that have significantly improved outcomes in multiple myeloma (MM), it remains an incurable disease. Patients with relapsed and/or refractory MM have an aggressive disease course, with inferior outcomes, necessitating the need for agents with novel therapeutic mechanisms. We present the results of a completed phase I trial of single-agent lorvotuzumab mertansine, a unique antibody-drug conjugate targeting CD56, which is frequently expressed in MM.Thirty-seven patients with relapsed MM were enrolled in a dose-escalation phase I clinical trial to determine the maximum tolerated dose of lorvotuzumab mertansine (112 mg/m2), followed by an expansion phase at the maximum tolerated dose.Despite a high proportion of patients with relapsed and/or refractory MM (56.8%), stable disease or better was noted in 42.9% of patients, and these patients had a long duration of response (median, 15.5 months). The adverse event profile was favorable, with a low incidence of grade 3/4 adverse events and no infusion-related reactions. No humoral responses were detected against the study drug.This completed phase I trial of single-agent lorvotuzumab mertansine provides ample evidence of safety and signals of clinical activity for this agent, warranting its further clinical development as part of combination regimens for the management of MM." @default.
• W2891360972 created "2018-09-27" @default.
• W2891360972 creator A5004027885 @default.
• W2891360972 creator A5005922094 @default.
• W2891360972 creator A5010286156 @default.
• W2891360972 creator A5013824370 @default.
• W2891360972 creator A5028046297 @default.
• W2891360972 creator A5044589378 @default.
• W2891360972 creator A5052345783 @default.
• W2891360972 creator A5077313033 @default.
• W2891360972 creator A5077764285 @default.
• W2891360972 creator A5087596911 @default.
• W2891360972 date "2019-01-01" @default.
• W2891360972 modified "2023-10-10" @default.
• W2891360972 title "A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma" @default.
• W2891360972 cites W1883871705 @default.
• W2891360972 cites W1978377409 @default.
• W2891360972 cites W2000130439 @default.
• W2891360972 cites W2010566371 @default.
• W2891360972 cites W2020431842 @default.
• W2891360972 cites W2035900357 @default.
• W2891360972 cites W2082863510 @default.
• W2891360972 cites W2094651737 @default.
• W2891360972 cites W2098628589 @default.
• W2891360972 cites W2100545964 @default.
• W2891360972 cites W2106333492 @default.
• W2891360972 cites W2129703550 @default.
• W2891360972 cites W2160088903 @default.
• W2891360972 cites W2165168809 @default.
• W2891360972 cites W2201190784 @default.
• W2891360972 cites W2216303864 @default.
• W2891360972 cites W2229483068 @default.
• W2891360972 cites W2288822655 @default.
• W2891360972 cites W2301784755 @default.
• W2891360972 cites W2311936801 @default.
• W2891360972 cites W2402003835 @default.
• W2891360972 cites W2512106959 @default.
• W2891360972 cites W2528329272 @default.
• W2891360972 cites W2528730592 @default.
• W2891360972 cites W2535853965 @default.
• W2891360972 cites W2568399389 @default.
• W2891360972 cites W2570618306 @default.
• W2891360972 cites W2592799965 @default.
• W2891360972 cites W2781388087 @default.
• W2891360972 cites W2792774731 @default.
• W2891360972 cites W4250459881 @default.
• W2891360972 doi "https://doi.org/10.1016/j.clml.2018.08.018" @default.
• W2891360972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30340993" @default.
• W2891360972 hasPublicationYear "2019" @default.
• W2891360972 type Work @default.
• W2891360972 sameAs 2891360972 @default.
• W2891360972 citedByCount "51" @default.
• W2891360972 countsByYear W28913609722019 @default.
• W2891360972 countsByYear W28913609722020 @default.
• W2891360972 countsByYear W28913609722021 @default.
• W2891360972 countsByYear W28913609722022 @default.
• W2891360972 countsByYear W28913609722023 @default.
• W2891360972 crossrefType "journal-article" @default.
• W2891360972 hasAuthorship W2891360972A5004027885 @default.
• W2891360972 hasAuthorship W2891360972A5005922094 @default.
• W2891360972 hasAuthorship W2891360972A5010286156 @default.
• W2891360972 hasAuthorship W2891360972A5013824370 @default.
• W2891360972 hasAuthorship W2891360972A5028046297 @default.
• W2891360972 hasAuthorship W2891360972A5044589378 @default.
• W2891360972 hasAuthorship W2891360972A5052345783 @default.
• W2891360972 hasAuthorship W2891360972A5077313033 @default.
• W2891360972 hasAuthorship W2891360972A5077764285 @default.
• W2891360972 hasAuthorship W2891360972A5087596911 @default.
• W2891360972 hasBestOaLocation W28913609722 @default.
• W2891360972 hasConcept C112705442 @default.
• W2891360972 hasConcept C120665830 @default.
• W2891360972 hasConcept C121332964 @default.
• W2891360972 hasConcept C126322002 @default.
• W2891360972 hasConcept C141071460 @default.
• W2891360972 hasConcept C142424586 @default.
• W2891360972 hasConcept C143998085 @default.
• W2891360972 hasConcept C197934379 @default.
• W2891360972 hasConcept C2776364478 @default.
• W2891360972 hasConcept C31760486 @default.
• W2891360972 hasConcept C535046627 @default.
• W2891360972 hasConcept C61511704 @default.
• W2891360972 hasConcept C71924100 @default.
• W2891360972 hasConcept C87355193 @default.
• W2891360972 hasConcept C90924648 @default.
• W2891360972 hasConceptScore W2891360972C112705442 @default.
• W2891360972 hasConceptScore W2891360972C120665830 @default.
• W2891360972 hasConceptScore W2891360972C121332964 @default.
• W2891360972 hasConceptScore W2891360972C126322002 @default.
• W2891360972 hasConceptScore W2891360972C141071460 @default.
• W2891360972 hasConceptScore W2891360972C142424586 @default.
• W2891360972 hasConceptScore W2891360972C143998085 @default.
• W2891360972 hasConceptScore W2891360972C197934379 @default.
• W2891360972 hasConceptScore W2891360972C2776364478 @default.
• W2891360972 hasConceptScore W2891360972C31760486 @default.
• W2891360972 hasConceptScore W2891360972C535046627 @default.
• W2891360972 hasConceptScore W2891360972C61511704 @default.
• W2891360972 hasConceptScore W2891360972C71924100 @default.
• W2891360972 hasConceptScore W2891360972C87355193 @default.

• next